Researchers are advancing CRISPR-based antivirals that could revolutionize how we fight seasonal and pandemic influenza by directly disabling the virus’s RNA. According to Wired’s science coverage, scientists at the Peter Doherty Institute in Melbourne are developing CRISPR-Cas13 systems delivered via lipid nanoparticles as nasal sprays or injections to target conserved flu RNA segments, potentially stopping replication across strains where drugs like Tamiflu fall short. Early lab models, including Harvard Wyss Institute human lung “Organ Chips,” demonstrate that these therapies can reduce viral replication and inflammation with minimal off-target effects in human-like tissues. Independent preclinical studies using advanced Lung Chip models at Harvard show CRISPR RNA therapies can cut influenza A viral load by more than 50% and blunt harmful immune responses, positioning CRISPR tools as pan-influenza antiviral candidates. Ongoing research underscores both the promise and challenges—particularly delivery to deep lung tissue and ensuring safety—before human clinical use is viable.
Sources:
https://www.wired.com/story/crispr-flu-antivirals/
https://medicalxpress.com/news/2025-10-human-chip-technology-stage-pan.html
https://www.news-medical.net/news/20251015/CRISPR-therapy-shows-promise-against-influenza-in-human-lung-chips.aspx
Key Takeaways
• CRISPR-Cas13 antivirals aim at highly conserved influenza RNA to overcome strain-specific resistance in existing treatments.
• Human Lung Chip models provide a more clinically relevant testing platform, showing significant viral reduction and minimal off-target effects.
• Delivery challenges and safety considerations remain major hurdles before CRISPR antivirals reach clinical use.
In-Depth
Scientists are increasingly looking beyond conventional flu vaccines and small-molecule drugs to gene-editing technologies like CRISPR as a powerful new class of antivirals. Traditional flu drugs often struggle because influenza mutates quickly and adapts to evade antiviral mechanisms. The CRISPR approach, particularly using the Cas13 RNA-targeting enzyme, could cut right through that problem by homing in on parts of the virus’s genome that are integral to its ability to replicate and shared across many strains. Wired recently highlighted how researchers are developing systems that deliver the CRISPR machinery directly into infected cells in the respiratory tract, using lipid nanoparticles as a transport vehicle. Once inside, the CRISPR system would snip viral RNA at critical sites, effectively halting replication at its genetic root.
One major advance facilitating this research has been the use of human Lung Chip models—tiny microfluidic devices that mimic the structure and breathing motion of human lung tissue much more accurately than animal models. Results reported in multiple preclinical studies show that CRISPR RNA therapies delivered to these Lung Chips achieve significant reductions in viral load, often by more than half, and also dampen the inflammatory responses that contribute to flu symptoms and complications. These chips also allow researchers to assess off-target effects more precisely, with initial data suggesting minimal unintended editing in human cells.
Still, it’s early days. Experts acknowledge substantial challenges ahead, especially in effectively delivering these CRISPR components deep into human lungs and avoiding immune reactions against the bacterial proteins involved. But the combination of sophisticated delivery methods and human-based testing platforms means CRISPR antivirals may someday offer a durable, broad-spectrum defense against flu that conventional strategies can’t match. If realized, such therapies could not only improve seasonal flu outcomes but also provide frontline tools against future pandemic strains that currently catch public health systems off guard.